Recently, p53 stabilization combined with BET inhibitor-mediated chromatin disruption was able to efficiently kill CD34+ cells from CML patients, highly enriched for CML-LSCs (75). This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.